Exagen Other Stockholder Equity from 2010 to 2024
| XGN Stock | USD 1.92 0.12 5.88% |
Other Stockholder Equity | First Reported 2013-03-31 | Previous Quarter 301.9 M | Current Value 302.6 M | Quarterly Volatility 119.7 M |
Check Exagen financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Exagen's main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.3 M, Interest Expense of 2.8 M or Total Revenue of 32.2 M, as well as many indicators such as Price To Sales Ratio of 0.64, Dividend Yield of 0.0 or PTB Ratio of 1.18. Exagen financial statements analysis is a perfect complement when working with Exagen Valuation or Volatility modules.
Exagen | Other Stockholder Equity |
Latest Exagen's Other Stockholder Equity Growth Pattern
Below is the plot of the Other Stockholder Equity of Exagen Inc over the last few years. It is Exagen's Other Stockholder Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Exagen's overall financial position and show how it may be relating to other accounts over time.
| Other Stockholder Equity | 10 Years Trend |
|
Other Stockholder Equity |
| Timeline |
Exagen Other Stockholder Equity Regression Statistics
| Arithmetic Mean | 131,850,293 | |
| Geometric Mean | 97,456,490 | |
| Coefficient Of Variation | 80.02 | |
| Mean Deviation | 94,632,085 | |
| Median | 57,250,000 | |
| Standard Deviation | 105,509,876 | |
| Sample Variance | 11132.3T | |
| Range | 259.5M | |
| R-Value | 0.79 | |
| Mean Square Error | 4495.8T | |
| R-Squared | 0.62 | |
| Significance | 0.0005 | |
| Slope | 18,651,581 | |
| Total Sum of Squares | 155852.7T |
Exagen Other Stockholder Equity History
About Exagen Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Exagen income statement, its balance sheet, and the statement of cash flows. Exagen investors use historical funamental indicators, such as Exagen's Other Stockholder Equity, to determine how well the company is positioned to perform in the future. Although Exagen investors may use each financial statement separately, they are all related. The changes in Exagen's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Exagen's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Exagen Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Exagen. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Other Stockholder Equity | 301.9 M | 164.6 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectAdditional Information and Resources on Investing in Exagen Stock
When determining whether Exagen Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Exagen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Exagen Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Exagen Inc Stock:Check out the analysis of Exagen Correlation against competitors. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Exagen. If investors know Exagen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Exagen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.09) | Revenue Per Share 3.134 | Quarterly Revenue Growth 0.284 | Return On Assets (0.17) | Return On Equity (0.69) |
The market value of Exagen Inc is measured differently than its book value, which is the value of Exagen that is recorded on the company's balance sheet. Investors also form their own opinion of Exagen's value that differs from its market value or its book value, called intrinsic value, which is Exagen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Exagen's market value can be influenced by many factors that don't directly affect Exagen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Exagen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Exagen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Exagen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.